tert-butyl 4-(1H-pyrrolo[2,3-b]pyridin-3-yl)piperidine-1-carboxylate | 400801-83-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: tert-butyl 4-(1H-pyrrolo[2,3-b]pyridin-3-yl)piperidine-1-carboxylate
• CAS: 400801-83-4
• 化学式: C₁₇H₂₃N₃O₂
• 分子量: 301.389
• InChiKey: LUFMOZOQECBNQC-UHFFFAOYSA-N

物化性质

• 密度：
  1.184±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  58.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(1H-pyrrolo[2,3-b]pyridin-3-yl)piperidine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 3-(4-哌啶基)-1H-吡咯并[2,3-b]吡啶
  参考文献：
  名称：

  Pyrazole-based cathepsin S inhibitors with improved cellular potency

  摘要：

  High potency pyrazole-based noncovalent inhibitors of human cathepsin S (CatS) were developed by modification of the benzo-fused 5-membered ring heterocycles found in earlier series of Cats inhibitors. Although substitutions on this heterocyclic framework had a moderate impact on enzymatic potency, dramatic effects on cellular activity were observed. Optimization afforded indole- and benzothiophene-derived analogues that were high affinity Cats inhibitors (IC50 = 20-40 nM) with good cellular potency (IC50 = 30-340 nM). (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.08.038
• 作为产物：
  描述：

  7-氮杂吲哚 在 palladium 10% on activated carbon 、 氢气 、 sodium methylate 、 溶剂黄146 作用下， 以 甲醇 为溶剂， 反应 50.5h， 生成 tert-butyl 4-(1H-pyrrolo[2,3-b]pyridin-3-yl)piperidine-1-carboxylate
  参考文献：
  名称：

  发现和表征新型的吲哚和7-氮杂吲哚衍生物作为β-淀粉样蛋白42聚集的抑制剂，用于治疗阿尔茨海默氏病。

  摘要：

  淀粉状蛋白-β肽聚集为细胞毒性寡聚体和原纤维聚集体被认为是阿尔茨海默病的主要病理事件之一。在这里，我们报告设计和合成一系列新的吲哚和7-氮杂吲哚衍生物，它们在3位上含有腈，哌啶和N-甲基-哌啶取代基，以防止淀粉样β的病理自组装。我们进一步证明，为了获得具有改善的理化特性以允许脑渗透的化合物，需要在3个位置取代氮杂吲哚和吲哚衍生物。

  DOI：

  10.1016/j.bmcl.2017.02.001

文献信息

• Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins
  申请人：Kroth Heiko

  公开号：US20110280808A1

  公开（公告）日：2011-11-17

  The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed.

  本发明涉及一种新型化合物，可用于治疗与淀粉样蛋白相关的一组疾病和异常，如阿尔茨海默病，以及与淀粉样蛋白类似蛋白相关的疾病或病况。本发明的化合物还可用于治疗与视觉系统组织中的病理异常/变化相关的眼部疾病。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物制备用于治疗或预防与淀粉样和/或淀粉样类似蛋白相关的疾病或病况的药物的用途。还公开了一种治疗或预防与淀粉样和/或淀粉样类似蛋白相关的疾病或病况的方法。
• Discovery and characterization of novel indole and 7-azaindole derivatives as inhibitors of β-amyloid-42 aggregation for the treatment of Alzheimer’s disease
  作者：Nampally Sreenivasachary、Heiko Kroth、Pascal Benderitter、Anne Hamel、Yvan Varisco、David T. Hickman、Wolfgang Froestl、Andrea Pfeifer、Andreas Muhs

  DOI：10.1016/j.bmcl.2017.02.001

  日期：2017.3

  design and synthesis of a novel series of indole and 7-azaindole derivatives containing, nitrile, piperidine and N-methyl-piperidine substituents at the 3-position to prevent the pathological self-assembly of amyloid-β. We have further demonstrated that substitution of the azaindole and indole derivatives at the 3 positions is required to obtain compounds with improved physicochemical properties to allow

  淀粉状蛋白-β肽聚集为细胞毒性寡聚体和原纤维聚集体被认为是阿尔茨海默病的主要病理事件之一。在这里，我们报告设计和合成一系列新的吲哚和7-氮杂吲哚衍生物，它们在3位上含有腈，哌啶和N-甲基-哌啶取代基，以防止淀粉样β的病理自组装。我们进一步证明，为了获得具有改善的理化特性以允许脑渗透的化合物，需要在3个位置取代氮杂吲哚和吲哚衍生物。
• [EN] AZAINDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS<br/>[FR] DERIVES D'AZAINDOLYLPIPERIDINE COMME AGENTS ANTIHISTAMINIQUES ET ANTIALLERGIQUES
  申请人：ALMIRALL PRODESFARMA SA

  公开号：WO2003082867A1

  公开（公告）日：2003-10-09

  This invention is directed to new potent and selective antagonists of H1 histamine receptors having the general formula (I) to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy.

  这项发明涉及新型H1组胺受体的高效选择性拮抗剂，其具有一般式(I)，以及它们的制备方法；包含它们的药物组合物；以及它们在治疗中的应用。
• [EN] BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS<br/>[FR] DÉRIVÉS BICYCLIQUES DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT D'AFFECTIONS ASSOCIÉES AU RÉCEPTEUR DES ANDROGÈNES
  申请人：ASTRAZENECA AB

  公开号：WO2009081197A1

  公开（公告）日：2009-07-02

  The invention concerns bicyclic compounds of Formula (I), wherein the integers X1, X2, X3, Ring A, R4, R5 and m are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of androgen-receptor associated conditions.

  该发明涉及式(I)的双环化合物，其中整数X1、X2、X3、环A、R4、R5和m的定义如描述中所示。本发明还涉及制备这些化合物的方法、含有它们的药物组合物以及它们在制备用于预防或治疗雄激素受体相关疾病的药物中的应用。
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：AC IMMUNE SA

  公开号：WO2022078971A1

  公开（公告）日：2022-04-21

  The present invention relates to novel compounds that can be employed in the treatment, alleviation or prevention of a group of diseases, disorders and or abnormality associated with misfolding of Tau protein and/or pathological aggregation of Tau (Tubulin associated unit) protein including, but not limited to, Neurofibrillary Tangles (NFTs), such as Alzheimer's disease (AD). The present invention also relates to processes for the preparation of said compounds, pharmaceutical compositions comprising said compounds, methods using said compounds, combinations comprising said compounds, medicaments containing them, and their uses in diseases, disorders and/or abnormalities associated with misfolding of Tau protein and/or pathological aggregation of Tau (Tubulin associated unit) protein.

  本发明涉及一类新化合物，可用于治疗、缓解或预防一组与Tau蛋白误折叠和/或Tau（微管相关单元）蛋白的病理聚集有关的疾病、疾病和/或异常，包括但不限于神经纤维缠结（NFT），如阿尔茨海默病（AD）。本发明还涉及制备所述化合物的方法，包括所述化合物的制药组合物，使用所述化合物的方法，包括所述化合物的组合物，含有它们的药物以及它们在与Tau蛋白误折叠和/或Tau（微管相关单元）蛋白的病理聚集有关的疾病、疾病和/或异常中的用途。